Patents by Inventor Dirk HOSE

Dirk HOSE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 AND BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3
    Publication number: 20250230256
    Abstract: The present invention relates to a bispecific antibody which bind to human carcinoembryonic antigen CEACAM5 and to human CD47 for use in the treatment of cancer with a bispecific antibody which bind to human carcinoembryonic antigen CEACAM5 and to human CD3?, such combination and their use in the treatment of diseases.
    Type: Application
    Filed: June 15, 2023
    Publication date: July 17, 2025
    Inventors: Vanessa BUATOIS, Anja SECKINGER, Dirk HOSE
  • Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
    Patent number: 12122850
    Abstract: The present invention relates to GPC3×CD3 bispecific antibodies, GPC3×CD28 bispecific antibodies and the combination of two, agonistic and fully human KA-bodies with one targeting GPC3×CD3 and the other targeting GPC3×CD28, and both not competing for the binding to GPC3. The present invention also relates to the use of the bispecific antibodies for the treatment of GPC3 positive malignancies.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: October 22, 2024
    Assignee: LamKap Bio gamma AG
    Inventors: Eric Hatterer, Anja Seckinger, Dirk Hose
  • BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47
    Publication number: 20240101705
    Abstract: The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 and human CD47. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases. The invention also relates to the therapeutic use of the bispecific antibodies in monotherapy and in combination therapy.
    Type: Application
    Filed: July 31, 2023
    Publication date: March 28, 2024
    Inventors: Vanessa BUATOIS, Dirk HOSE, Anja SECKINGER
  • BISPECIFIC GPC3xCD28 AND GPC3xCD3 ANTIBODIES AND THEIR COMBINATION FOR TARGETED KILLING OF GPC3 POSITIVE MALIGNANT CELLS
    Publication number: 20230287146
    Abstract: The present invention relates to GPC3×CD3 bispecific antibodies, GPC3×CD28 bispecific antibodies and the combination of two, agonistic and fully human ??-bodies with one targeting GPC3×CD3 and the other targeting GPC3×CD28, and both not competing for the binding to GPC3. The present invention also relates to the use of the bispecific antibodies for the treatment of GPC3 positive malignancies.
    Type: Application
    Filed: March 14, 2023
    Publication date: September 14, 2023
    Inventors: Eric HATTERER, Anja SECKINGER, Dirk HOSE
  • Bispecific antibodies against CEACAM5 and CD47
    Patent number: 11753481
    Abstract: The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 and human CD47. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases. The invention also relates to the therapeutic use of the bispecific antibodies in monotherapy and in combination therapy.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: September 12, 2023
    Assignee: LAMKAP BIO BETA LTD
    Inventors: Vanessa Buatois, Dirk Hose, Anja Seckinger
  • BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47
    Publication number: 20220195067
    Abstract: The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 and human CD47. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases. The invention also relates to the therapeutic use of the bispecific antibodies in monotherapy and in combination therapy.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 23, 2022
    Inventors: Vanessa BUATOIS, Dirk HOSE, Anja SECKINGER